Octocrylene
Anthelios, Capital Soleil (octocrylene) is a small molecule pharmaceutical. Octocrylene was first approved as Anthelios sx on 2006-07-21.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Ecamsule
+
Octocrylene
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| OTC monograph not final | 2012-08-20 | |
| (re)setting refreshing mist spf 40 | OTC monograph final | 2022-10-13 |
| 1000 roses daily shade facial spf 18 | OTC monograph final | 2019-07-15 |
| 24/7 life by 7- eleven | OTC monograph final | 2022-06-23 |
| 24/7 life by 7-eleven | OTC monograph final | 2022-11-07 |
| 2x sunblock spf 50 | OTC monograph final | 2011-04-28 |
| 3-in-1 face moisturizer broad spectrum spf 20 | OTC monograph final | 2019-03-27 |
| 360 by qur lemon verbena lip balm | C200263 | 2023-10-26 |
| 360 by qur spanish lime lip balm | C200263 | 2023-10-26 |
| 360 by qur vanilla lace lip balm | C200263 | 2023-10-26 |
Show 2138 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanosis | D008548 | HP_0001480 | L81.1 | — | — | — | 1 | — | 1 |
| Sunburn | D013471 | EFO_0003958 | L55 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Photoallergic dermatitis | D017454 | — | L56.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Octocrylene |
| INN | octocrilene |
| Description | Octocrylene is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 6197-30-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201147 |
| ChEBI ID | — |
| PubChem CID | 22571 |
| DrugBank | — |
| UNII ID | 5A68WGF6WM (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 407 documents
View more details
Safety
Black-box Warning
Black-box warning for: Perfectly posh block it like its hot broad spectrum, Youth cell day cream broad spectrum spf-15 sunscreen (50 ml)
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
131,465 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use